The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Jul-2024
Active ingredients
tislelizumab
Proposed indication
For the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Application type
C (new indication)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.